Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-11-18 Purchase | 2024-11-20 4:11 pm | AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director | 25,000 | $1.0018 | $25,046 | 529,079 (Indirect Direct) | View |
| 2024-11-18 Purchase | 2024-11-18 8:51 pm | AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer | 50,000 | $0.9994 | $49,970 | 1,361,012 (Indirect Direct) | View |
| 2024-08-14 Purchase | 2024-08-14 8:24 pm | AN2 Therapeutics Inc. | ANTX | Leonard Braden Michael 10% Owner | 1,500,000 | $1.04 | $1,560,000 | 5,749,432 (Indirect) | View |
| 2024-08-09 Sale | 2024-08-13 5:03 pm | AN2 Therapeutics Inc. | ANTX | RA CAPITAL MANAGEMENT L.P. RA Capital Healthcare Fund LP RA Capital Nexus Fund II L.P. Kolchinsky Peter Shah Rajeev M. 10% Owner | 3,525,094 | $1.08 | $3,807,102 | 300,853 (Indirect) | View |
| 2024-01-18 Sale | 2024-01-19 7:32 pm | AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director | 100,000 | $19.11 | $1,911,410 | 504,079 (Indirect Direct) | View |
| 2024-01-16 Sale | 2024-01-18 6:19 pm | AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director | 100,000 | $19.65 | $1,965,000 | 377,542 (Indirect) | View |
| 2024-01-16 Sale | 2024-01-18 6:18 pm | AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. Adjuvant Capital GP L.P. Adjuvant Capital Management LLC 10% Owner | 100,000 | $19.65 | $1,965,000 | 2,373,500 (Indirect Direct) | View |
| 2024-01-12 Sale | 2024-01-17 5:03 pm | AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director | 1,425 | $21.91 | $31,229 | 485,073 (Indirect) | View |
| 2024-01-10 Sale | 2024-01-12 5:08 pm | AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director | 3,669 | $21.93 | $80,443 | 485,792 (Indirect) | View |
| 2024-01-09 Sale | 2024-01-11 7:59 pm | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 7,417 | $20.14 | $149,367 | 78,614 (Direct) | View |
| 2024-01-02 Sale | 2024-01-04 6:06 pm | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 2,583 | $20.12 | $51,967 | 54,199 (Direct) | View |
| 2024-01-02 Sale | 2024-01-04 6:05 pm | AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer | 2,777 | $20.09 | $55,802 | 1,212,012 (Indirect Direct) | View |
| 2023-11-14 Sale | 2023-11-16 6:59 pm | AN2 Therapeutics Inc. | ANTX | Adjuvant Global Health Technology Fund L.P. Adjuvant Global Health Technology Fund DE L.P. Adjuvant Capital GP L.P. Adjuvant Capital Management LLC 10% Owner | 1,810 | $16.15 | $29,224 | 2,473,500 (Indirect Direct) | View |
| 2023-11-14 Sale | 2023-11-16 6:57 pm | AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director 10% Owner | 1,810 | $16.15 | $29,224 | 393,449 (Indirect) | View |
| 2023-09-29 Sale | 2023-10-03 7:21 pm | AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director 10% Owner | 104,773 | $16.27 | $1,704,513 | 393,737 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-11-04 Option Award | 2024-11-05 4:57 pm | N/A 2034-11-03 | AN2 Therapeutics Inc. | ANTX | Prior Stephen David Chief Strategy Officer | 30,375 | $0 | 55,592 (Direct) | View |
| 2024-11-04 Option Award | 2024-11-05 4:51 pm | N/A 2034-11-03 | AN2 Therapeutics Inc. | ANTX | Eizen Joshua M See Remarks | 94,500 | $0 | 189,335 (Direct) | View |
Ownership | 2024-11-05 4:49 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Prior Stephen David Chief Strategy Officer | 0 | $0 | 135,417 (Direct) | View |
Ownership | 2024-08-12 4:58 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Leonard Braden Michael 10% Owner | 0 | $0 | 4,249,432 (Indirect) | View |
| 2024-07-10 Option Award | 2024-07-12 4:13 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Eizen Joshua M Chief Legal Officer | 60,000 | $0 | 94,833 (Direct) | View |
| 2024-06-19 Option Award | 2024-06-21 6:22 pm | N/A 2034-06-18 | AN2 Therapeutics Inc. | ANTX | Readnour Robin Shane Director | 64,503 | $0 | 64,503 (Direct) | View |
| 2024-06-19 Option Award | 2024-06-21 6:20 pm | N/A 2034-06-18 | AN2 Therapeutics Inc. | ANTX | Marks Gilbert Lynn Director | 64,503 | $0 | 64,503 (Direct) | View |
| 2024-06-19 Option Award | 2024-06-21 6:18 pm | N/A 2034-06-18 | AN2 Therapeutics Inc. | ANTX | FitzPatrick Margaret M Director | 64,503 | $0 | 64,503 (Direct) | View |
| 2024-06-19 Option Award | 2024-06-21 6:16 pm | N/A 2034-06-18 | AN2 Therapeutics Inc. | ANTX | Aziz Kabeer Director | 64,503 | $0 | 64,503 (Direct) | View |
| 2024-06-19 Option Award | 2024-06-21 6:12 pm | N/A 2034-06-18 | AN2 Therapeutics Inc. | ANTX | Zakrzewski Joseph S Director | 64,503 | $0 | 64,503 (Direct) | View |
| 2024-06-19 Option Award | 2024-06-21 5:58 pm | N/A 2034-06-18 | AN2 Therapeutics Inc. | ANTX | Spigelman Melvin K Director | 64,503 | $0 | 64,503 (Direct) | View |
| 2024-06-19 Option Award | 2024-06-21 5:56 pm | N/A 2034-06-18 | AN2 Therapeutics Inc. | ANTX | Martin Patricia A. Director | 64,503 | $0 | 64,503 (Direct) | View |
| 2024-06-19 Option Award | 2024-06-21 5:50 pm | N/A 2034-06-18 | AN2 Therapeutics Inc. | ANTX | Wong Stephanie Director | 64,503 | $0 | 64,503 (Direct) | View |
| 2024-03-15 Option Award(A) | 2024-03-29 4:19 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Eckburg Paul Chief Medical Officer | 30,000 | $0 | 51,416 (Direct) | View |
| 2024-03-15 Option Award(A) | 2024-03-29 4:18 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Day Lucy Chief Financial Officer | 27,500 | $0 | 30,627 (Direct) | View |
| 2024-03-15 Option Award(A) | 2024-03-29 4:18 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Eizen Joshua M Chief Legal Officer | 30,000 | $0 | 32,447 (Direct) | View |
| 2024-03-15 Option Award(A) | 2024-03-29 4:17 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 30,000 | $0 | 31,914 (Direct) | View |
| 2024-03-15 Option Award(A) | 2024-03-29 4:16 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Chanda Sanjay Chief Development Officer | 27,500 | $0 | 28,235 (Direct) | View |
| 2024-03-15 Option Award(A) | 2024-03-29 4:16 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer | 99,000 | $0 | 101,130 (Direct) | View |
| 2024-03-15 Option Award | 2024-03-18 7:29 pm | N/A 2034-03-14 | AN2 Therapeutics Inc. | ANTX | Day Lucy Chief Financial Officer | 82,500 | $0 | 85,627 (Direct) | View |
| 2024-03-15 Option Award | 2024-03-18 7:28 pm | N/A 2034-03-14 | AN2 Therapeutics Inc. | ANTX | Eizen Joshua M Chief Legal Officer | 90,000 | $0 | 92,447 (Direct) | View |
| 2024-03-15 Option Award | 2024-03-18 7:28 pm | N/A 2034-03-14 | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 90,000 | $0 | 91,914 (Direct) | View |
| 2024-03-15 Option Award | 2024-03-18 7:27 pm | N/A 2034-03-14 | AN2 Therapeutics Inc. | ANTX | Chanda Sanjay Chief Development Officer | 82,500 | $0 | 83,235 (Direct) | View |
| 2024-03-15 Option Award | 2024-03-18 7:27 pm | N/A 2034-03-14 | AN2 Therapeutics Inc. | ANTX | Eckburg Paul Chief Medical Officer | 90,000 | $0 | 111,416 (Direct) | View |
| 2024-03-15 Option Award | 2024-03-18 7:26 pm | N/A 2034-03-14 | AN2 Therapeutics Inc. | ANTX | Easom Eric Chief Executive Officer | 297,000 | $0 | 1,509,012 (Direct) | View |
| 2024-01-09 Exercise | 2024-01-11 7:59 pm | N/A 2030-01-22 | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 7,417 | $0 | 78,614 (Direct) | View |
| 2024-01-09 Exercise | 2024-01-11 7:59 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 5,000 | $6.6 | 78,614 (Direct) | View |
| 2024-01-09 Exercise | 2024-01-11 7:59 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 2,417 | $0.42 | 78,614 (Direct) | View |
| 2024-01-02 Exercise | 2024-01-04 6:06 pm | N/A 2030-01-22 | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 2,583 | $0 | 54,199 (Direct) | View |
| 2024-01-02 Exercise | 2024-01-04 6:06 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 2,583 | $0.42 | 54,199 (Direct) | View |